|
1
|
Porter PL: Global trends in breast cancer
incidence and mortality. Salud Publica Mex. 51(Suppl 2): S141–S146.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
MacMahon B: Epidemiology and the causes of
breast cancer. Int J Cancer. 118:2373–2378. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rossi RE, Pericleous M, Mandair D, Whyand
T and Caplin ME: The role of dietary factors in prevention and
progression of breast cancer. Anticancer Res. 34:6861–6875.
2014.PubMed/NCBI
|
|
4
|
Amani D, Khalilnezhad A, Ghaderi A,
Niikawa N and Yoshiura K: Transforming growth factor beta1 (TGFβ1)
polymorphisms and breast cancer risk. Tumour Biol. 35:4757–4764.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaidya JS, Baldassarre G, Thorat MA and
Massarut S: Role of glucocorticoids in breast cancer. Curr Pharm
Des. 16:3593–3600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Planque N and Perbal B: A structural
approach to the role of CCN (CYR61/CTGF/NOV) proteins in
tumourigenesis. Cancer Cell Int. 3:152003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian S, Roepman P, Van't Veer LJ, Bernards
R, de Snoo F and Glas AM: Biological functions of the genes in the
mammaprint breast cancer profile reflect the hallmarks of cancer.
Biomark Insights. 5:129–138. 2010.PubMed/NCBI
|
|
8
|
Holbourn KP, Acharya KR and Perbal B: The
CCN family of proteins: Structure-function relationships. Trends
Biochem Sci. 33:461–473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martin M: Researchers hope new database
becomes universal cancer genomics tool. J Natl Cancer Inst.
104:1045–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cingoz S, Altungoz O, Canda T, Saydam S,
Aksakoglu G and Sakizli M: DNA copy number changes detected by
comparative genomic hybridization and their association with
clinicopathologic parameters in breast tumors. Cancer Genet
Cytogenet. 145:108–114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dellas A, Torhorst J, Schultheiss E,
Mihatsch MJ and Moch H: DNA sequence losses on chromosomes 11p and
18q are associated with clinical outcome in lymph node-negative
ductal breast cancer. Clin Cancer Res. 8:1210–1216. 2002.PubMed/NCBI
|
|
12
|
Climent J, Martinez-Climent JA, Blesa D,
Garcia-Barchino MJ, Saez R, Sánchez-Izquierdo D, Azagra P, Lluch A
and Garcia-Conde J: Genomic loss of 18p predicts an adverse
clinical outcome in patients with high-risk breast cancer. Clin
Cancer Res. 8:3863–3869. 2002.PubMed/NCBI
|
|
13
|
Horlings HM, Lai C, Nuyten DS, Halfwerk H,
Kristel P, van Beers E, Joosse SA, Klijn C, Nederlof PM, Reinders
MJ, et al: Integration of DNA copy number alterations and
prognostic gene expression signatures in breast cancer patients.
Clin Cancer Res. 16:651–663. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han S, Park K, Shin E, Kim HJ, Kim JY, Kim
JY and Gwak G: Genomic change of chromosome 8 predicts the response
to taxane-based neoadjuvant chemotherapy in node-positive breast
cancer. Oncol Rep. 24:121–128. 2010.PubMed/NCBI
|
|
15
|
Raeder MB, Birkeland E, Trovik J, Krakstad
C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE,
et al: Integrated genomic analysis of the 8q24 amplification in
endometrial cancers identifies ATAD2 as essential to MYC-dependent
cancers. PLoS One. 8:e548732013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu G, Chong RA, Yang Q, Wei Y, Blanco MA,
Li F, Reiss M, Au JL, Haffty BG and Kang Y: MTDH activation by 8q22
genomic gain promotes chemoresistance and metastasis of
poor-prognosis breast cancer. Cancer Cell. 15:9–20. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie D, Nakachi K, Wang H, Elashoff R and
Koeffler HP: Elevated levels of connective tissue growth factor,
WISP-1, and CYR61 in primary breast cancers associated with more
advanced features. Cancer Res. 61:8917–8923. 2001.PubMed/NCBI
|
|
18
|
Chen PP, Li WJ, Wang Y, Zhao S, Li DY,
Feng LY, Shi XL, Koeffler HP, Tong XJ and Xie D: Expression of
Cyr61, CTGF, and WISP-1 correlates with clinical features of lung
cancer. PLoS One. 2:e5342007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Davies SR, Watkins G, Mansel RE and Jiang
WG: Differential expression and prognostic implications of the CCN
family members WISP-1, WISP-2, and WISP-3 in human breast cancer.
Ann Surg Oncol. 14:1909–1918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Davies SR, Davies ML, Sanders A, Parr C,
Torkington J and Jiang WG: Differential expression of the CCN
family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer
and the prognostic implications. Int J Oncol. 36:1129–1136.
2010.PubMed/NCBI
|
|
21
|
Kalashnikova EV, Revenko AS, Gemo AT,
Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD and Chen HW:
ANCCA/ATAD2 overexpression identifies breast cancer patients with
poor prognosis, acting to drive proliferation and survival of
triple-negative cells through control of B-Myb and EZH2. Cancer
Res. 70:9402–9412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong X, Moran MS, Zhao Y and Yang Q:
Inhibition of metadherin sensitizes breast cancer cells to AZD6244.
Cancer Biol Ther. 13:43–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song Z, Wang Y, Li C, Zhang D and Wang X:
Molecular Modification of Metadherin/MTDH impacts the sensitivity
of breast cancer to doxorubicin. PLoS One. 10:e01275992015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Epping MT, Meijer LA, Krijgsman O, Bos JL,
Pandolfi PP and Bernards R: TSPYL5 suppresses p53 levels and
function by physical interaction with USP7. Nat Cell Biol.
13:102–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pegoraro S, Ros G, Ciani Y, Sgarra R,
Piazza S and Manfioletti G: A novel HMGA1-CCNE2-YAP axis regulates
breast cancer aggressiveness. Oncotarget. 6:19087–19101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van 't Veer LJ, Dai H, van de Vijver MJ,
He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gevaert O, De Smet F, Timmerman D, Moreau
Y and De Moor B: Predicting the prognosis of breast cancer by
integrating clinical and microarray data with Bayesian networks.
Bioinformatics. 22:e184–e190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McCormick C, Leduc Y, Martindale D,
Mattison K, Esford LE, Dyer AP and Tufaro F: The putative tumour
suppressor EXT1 alters the expression of cell-surface heparan
sulfate. Nat Genet. 19:158–161. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brown DM and Ruoslahti E: Metadherin, a
cell surface protein in breast tumors that mediates lung
metastasis. Cancer Cell. 5:365–374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Julien S, Ivetic A, Grigoriadis A, QiZe D,
Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, et
al: Selectin ligand sialyl-Lewis x antigen drives metastasis of
hormone-dependent breast cancers. Cancer Res. 71:7683–7693. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saxena N, Banerjee S, Sengupta K, Zoubine
MN and Banerjee SK: Differential expression of WISP-1 and WISP-2
genes in normal and transformed human breast cell lines. Mol Cell
Biochem. 228:99–104. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie D, Yin D, Wang HJ, Liu GT, Elashoff R,
Black K and Koeffler HP: Levels of expression of CYR61 and CTGF are
prognostic for tumor progression and survival of individuals with
gliomas. Clin Cancer Res. 10:2072–2081. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okolicsanyi RK, van Wijnen AJ, Cool SM,
Stein GS, Griffiths LR and Haupt LM: Heparan sulfate proteoglycans
and human breast cancer epithelial cell tumorigenicity. J Cell
Biochem. 115:967–976. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Khoontawad J, Hongsrichan N, Chamgramol Y,
Pinlaor P, Wongkham C, Yongvanit P, Pairojkul C, Khuntikeo N,
Roytrakul S, Boonmars T and Pinlaor S: Increase of exostosin 1 in
plasma as a potential biomarker for opisthorchiasis-associated
cholangiocarcinoma. Tumour Biol. 35:1029–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu M, Ingle JN, Fridley BL, Buzdar AU,
Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, et
al: TSPYL5 SNPs: Association with plasma estradiol concentrations
and aromatase expression. Mol Endocrinol. 27:657–670. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lyu JH, Park DW, Huang B, Kang SH, Lee SJ,
Lee C, Bae YS, Lee JG and Baek SH: RGS2 suppresses breast cancer
cell growth via a MCPIP1-dependent pathway. J Cell Biochem.
116:260–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee SG, Su ZZ, Emdad L, Sarkar D and
Fisher PB: Astrocyte elevated gene-1 (AEG-1) is a target gene of
oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc.
Proc Natl Acad Sci USA. 103:17390–17395. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ciró M, Prosperini E, Quarto M, Grazini U,
Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M,
Christensen J and Helin K: ATAD2 is a novel cofactor for MYC,
overexpressed and amplified in aggressive tumors. Cancer Res.
69:8491–8498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Caron C, Lestrat C, Marsal S, Escoffier E,
Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla
E, et al: Functional characterization of ATAD2 as a new
cancer/testis factor and a predictor of poor prognosis in breast
and lung cancers. Oncogene. 29:5171–5181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hsia EY, Kalashnikova EV, Revenko AS, Zou
JX, Borowsky AD and Chen HW: Deregulated E2F and the AAA+
coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in
breast cancer. Mol Cancer Res. 8:183–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gudas JM, Payton M, Thukral S, Chen E,
Bass M, Robinson MO and Coats S: Cyclin E2, a novel G1 cyclin that
binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell
Biol. 19:612–622. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Z, Meng Q, Yu Q, Zhou Z and Li L:
Evaluation of c-myc and CCNE2 amplification in breast cancer with
quantitative multi-gene fluorescence in-situ hybridization.
Zhonghua Bing Li Xue Za Zhi. 43:455–458. 2014.(In Chinese).
PubMed/NCBI
|
|
46
|
Caldon CE, Sergio CM, Kang J,
Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black
MA, Miller LD, et al: Cyclin E2 overexpression is associated with
endocrine resistance but not insensitivity to CDK2 inhibition in
human breast cancer cells. Mol Cancer Ther. 11:1488–1499. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rogers S, Gloss BS, Lee CS, Sergio CM,
Dinger ME, Musgrove EA, Burgess A and Caldon CE: Cyclin E2 is the
predominant E-cyclin associated with NPAT in breast cancer cells.
Cell Div. 10:12015. View Article : Google Scholar : PubMed/NCBI
|
